Breast cancer drug remains on CDF after ‘significant concessions’


A breast cancer drug will remain on the list of treatments patients can access through the cancer drugs fund after the manufacturer made ‘significant concessions’ on the price.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here